Here are three things to know.
- Nevisense is intended to help clinicians detect early stages of malignant melanoma.
- Clinicians may use the device to further assess suspicious skin lesions with one or more characteristics of melanoma before conducting a biopsy.
- The device, which uses electrical signals to measure and assess the skin, should not be used to confirm a clinical melanoma diagnosis.
More articles on supply chain:
UPS to freeze 70k workers’ pensions: 3 things to know
Philips to acquire Spectranetics devicemaker for $2.2B: 5 things to know
Valeant ‘most exposed’ to generic competition by FDA’s new drug list, says analyst
